Novartis AG (NVS) Scheduled to Post Quarterly Earnings on Tuesday
Novartis AG (NYSE:NVS) will be issuing its quarterly earnings data before the market opens on Tuesday, October 24th. Analysts expect the company to announce earnings of $1.25 per share for the quarter.
Novartis AG (NYSE NVS) traded up 0.65% during midday trading on Monday, hitting $86.30. 2,155,808 shares of the stock traded hands. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The company has a market cap of $202.19 billion, a PE ratio of 31.51 and a beta of 0.73. The company’s 50-day moving average is $85.60 and its 200-day moving average is $82.21.
NVS has been the subject of a number of recent analyst reports. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Novartis AG in a report on Tuesday, September 26th. Zacks Investment Research lowered shares of Novartis AG from a “buy” rating to a “hold” rating in a report on Thursday, September 21st. BidaskClub raised shares of Novartis AG from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Morgan Stanley raised shares of Novartis AG from an “underweight” rating to an “overweight” rating in a report on Wednesday, July 26th. Finally, Cowen and Company set a $90.00 price target on shares of Novartis AG and gave the company a “hold” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $84.13.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.